Friday, October 06, 2017 2:42:47 PM
http://www.otipharma.com/wp-content/uploads/2017/03/OT-short-presentation-03-16-2017-V-2.0.pdf see in a presentation in Oxygen site.
Dr. Ben-Zion Weiner, PhD
SCIENTIFIC ADVISORY BOARD CHAIRMAN
Dr. Ben-Zion Weiner was Head of Global
Research and Development at Teva
Pharmaceutical Industries Ltd. for over three
decades, including as a member of the Teva
Executive Committee. He directly oversaw all
pharmaceutical development and regulatory
approval of Teva’s innovative product pipeline.
Dr. Weiner was also responsible for the
development of hundreds of generic products
for the US, European, and other markets. He
received a BSc degree in general chemistry
and biochemistry and an MSc degree in
organic chemistry, graduating with distinction
for both degrees from the Hebrew University,
Jerusalem. He received his PhD degree in
chemistry at the Hebrew University,
Jerusalem, and conducted his post-doctoral
research at Schering-Plough Corporation in
the United States.
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM